MDxHealth

MDxHealth ROCE

Delisted

The Return on Capital Employed (ROCE) of MDxHealth (MDXH.BR) as of Oct 31, 2026 is 191.95 %. In the previous year, Return on Capital Employed (ROCE) was -202.53 % — a change of -194.78% (higher).

ROCE

191.95 %

YoY

-194.78%

Last updated:

In 2025, MDxHealth's return on capital employed (ROCE) was 191.95 %, a -194.78% increase from the -202.53 % ROCE in the previous year.

The MDxHealth ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2018
-61.59 USD
Jan 1, 2019
-218.83 USD
Jan 1, 2020
-466.95 USD
Jan 1, 2021
-57.84 USD
Jan 1, 2022
-443.38 USD
Jan 1, 2023
-442.61 USD
Jan 1, 2024
-202.53 USD
Jan 1, 2025
191.95 USD
The MDxHealth ROCE history
YEARROCEYoY
191.95 %-194.78%
-202.53 %-54.24%
-442.61 %-0.18%
-443.38 %+666.55%
-57.84 %-87.61%
-466.95 %+113.38%
-218.83 %+255.31%
-61.59 %+116.27%
-28.48 %+16.92%
-24.36 %-25.04%
-32.49 %-49.64%
-64.53 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MDxHealth Stock analysis

What does MDxHealth do? MDxHealth SA was founded in 2003 and is a publicly traded company based in Belgium, specializing in the development and marketing of molecular diagnostic tests for cancer diagnosis. The company focuses on developing tests for the diagnosis of prostate, bladder, and kidney cancer, as well as tests for monitoring the progression of these cancer types. The business model of MDxHealth is to develop state-of-the-art molecular diagnostics for cancer medicine and make them accessible to medical professionals and pathologists. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth also provides support to its customers in interpreting test results and choosing the best treatment options for patients. The company has different divisions tailored to the specific needs of patients, doctors, and pathologists. The main divisions are the oncology division and the urology division. In the oncology division, MDxHealth offers various tests for prostate cancer, including the Prognostic Oncotype DX Test used for predicting the progression of prostate cancer. The urology division of MDxHealth focuses on developing tests for bladder cancer and kidney cancer. The key tests in this division include the ConfirmMDx Test used for diagnosing bladder cancer, and the SelectMDx Test used for diagnosing aggressive prostate cancer. MDxHealth also has a significant presence in genomics and personalized medicine. The company partners with the University of Miami Miller School of Medicine to research and improve the application of genetic tests in cancer diagnosis and treatment. MDxHealth also collaborates closely with other leading research institutions and cancer centers to drive innovation in molecular diagnostics. Overall, MDxHealth offers a wide range of molecular diagnostic tests for cancer diagnosis and monitoring. The company has a strong presence in the US and Europe, and works closely with leading cancer centers and clinics to promote the use of the tests and improve their effectiveness. MDxHealth is a key player in the field of molecular diagnostics and has the potential to improve the lives of cancer patients worldwide. MDxHealth is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling MDxHealth's Return on Capital Employed (ROCE)

MDxHealth's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing MDxHealth's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

MDxHealth's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in MDxHealth’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about MDxHealth stock

Return on Capital Employed (ROCE) of MDxHealth is 191.95 % in 2025.

Return on Capital Employed (ROCE) of MDxHealth changed from -202.53 % to 191.95 %, representing a -194.78% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) MDxHealth since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s MDxHealth with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — MDxHealth

All Key Metrics — MDxHealth